Meriggioli M N, Rowin J
Rush-Presbyterian-St. Luke's Medical Center, Section of Neuromuscular Disorders, Department of Neurological Sciences, Chicago, Illinois 60612, USA.
Muscle Nerve. 2000 Aug;23(8):1287-9. doi: 10.1002/1097-4598(200008)23:8<1287::aid-mus22>3.0.co;2-l.
We report a patient with myasthenia gravis (MG) who had marked clinical benefit in response to treatment with mycophenolate mofetil as documented by serial quantitative measures of strength and muscle fatigue. Our patient had experienced either adverse side effects or a suboptimal response to the usual immunosuppressive agents used in MG. Mycophenolate mofetil was used in combination with cyclosporine and prednisone and allowed for significant reductions in dosage of these immunosuppressants. We conclude that mycophenolate mofetil deserves further study as a therapeutic agent in MG. In particular, its role as a steroid-sparing agent and as a drug to be used in combination immunotherapy in more severe or refractory cases of MG should be investigated.
我们报告了一名重症肌无力（MG）患者，通过对肌力和肌肉疲劳的系列定量测量证明，霉酚酸酯治疗使其临床症状显著改善。我们的患者对MG常用的免疫抑制剂出现了不良反应或反应欠佳。霉酚酸酯与环孢素和泼尼松联合使用，使这些免疫抑制剂的剂量得以大幅减少。我们得出结论，霉酚酸酯作为MG的一种治疗药物值得进一步研究。特别是，应研究其作为类固醇替代药物以及在MG更严重或难治性病例中作为联合免疫治疗药物的作用。
